Magnus Persson, MD PhD
Chairman of the Board
Magnus Persson is a Physician and an associate Professor in Physiology at the Karolinska Institutet in Stockholm. Magnus has 15 years of Partner level experience from Venture Capital and has been a Partner in two Life Sciences Venture Capital firms, one with its base in Sweden and with global reach and one in The Bay Area in California. Magnus has a long experience in medicine, life sciences and biotech financing. He has led development teams of Phase II and III programs in the Pharmaceutical Industry. He has founded and led private as well as public biotech and medtech companies as Chairman of the Board and Director in Europe and USA. All in all, he has more than 90 Board years in the life science industry and has been involved in a dozen IPOs.
Karen Wagner, PhD
Karen Wagner is a senior executive and entrepreneur with 20 years’ experience in the biopharmaceutical industry. Karen is General Partner at Ysios Capital and has a leading role in the investment team. Prior to joining Ysios at inception in 2008, she was a Global Alliance Director for F. Hoffmann-La Roche in Basel, Switzerland. Previously, she gained hands-on management experience at GLYCART, a biotech company in the antibody engineering space, which was acquired by Roche in 2005. Karen has also worked as a strategy consultant at McKinsey. In addition to Galecto, she serves on the Boards of Aelix, Vivet, Minoryx and Xeltis. In recent years Karen has been a board member of Kala (IPO on Nasdaq in 2017) and Cardoz. She holds a master’s degree in Molecular Biology and a PhD in Cell Biology.
Chau Khuong, MPH
Chau Q. Khuong is a Partner at OrbiMed, a healthcare dedicated investment firm with approximately $12 billion AUM. Mr. Khuong focuses on venture capital activities and has invested in novel drugs and therapeutic devices across a broad range of disease areas from oncology to infectious diseases to ophthalmology. Prior to OrbiMed, he developed skills in start-up operations and business development at Veritas Medicine, Inc. and in basic immunology research at the Yale School of Medicine and Massachusetts General Hospital. He serves or has served as a Board representative for drug and medical device development companies such as Arius (acquired by Roche), Glaukos (NYSE: GKOS), Graybug Vision, Inspire MedSystems (NYSE: INSP), Intercept Pharma (NASDAQ: ICPT), NextCure, Pieris Pharmaceuticals (NASDAQ: PIRS), Rempex Pharmaceuticals (acquired by Medicines Co.), ReViral Ltd, Sonendo, and Synlogic (NASDAQ: SYBX). Mr. Khuong holds a B.S. in molecular, cellular and developmental biology and M.P.H. with concentration in infectious disease, both from Yale University.
Søren Lemonius, MSc
Søren Lemonius partner at Sunstone Capital and has previously spent 10+ years in corporate management. During five years as CTO at Danionics, He participated in developing the company from a 30 employee technology company to a €27+ million, 300+ employees, product selling, listed company. He was responsible for releasing three new product generations. Before joining Danionics, Mr. Lemonius was Innovation Manager at FOSS Analytical, a private, €130+ million developer and producer of analytical equipment. Søren established and developed FOSS’s Innovation Center as a “First Responder” to new project and product opportunities. Søren also serves on the board of Atonomics A/S, Biomonitor A/S, TD Vaccine A/S and Nuevolution A/S.
Chandra Leo, MD MBA
Chandra P. Leo joined the Private Equity Team of HBM Partners in 2007. His board and investment experience includes biotech and medtech companies such as ChemoCentryx (IPO NASDAQ), ESBATech (acquired by Alcon/Novartis), Homology Medicines (IPO NASDAQ), ObsEva (IPO NASDAQ), Symbiomix Therapeutics (acquired by Lupin), CardiacAssist (acquired by LivaNova) and Gynesonics.
Prior to HBM, Chandra served as a postdoctoral scientist at Stanford University Medical Center, as a physician at the University Hospital Leipzig (Germany) and as a principal in the life sciences team at Wellington Partners. He completed his medical studies in Berlin and London and holds a doctoral degree from the Freie Universität Berlin (Charité) and an MBA degree with distinction from INSEAD.
Erez Chimovitz, MBA MSc
Erez Chimovits is a Senior Managing Director. Erez has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed Erez was the CEO of NasVax (TASE:NSVX). NasVax acquired Protea and struck agreements with GlaxoSmithKline and Novartis. Previously, Erez spent more than seven years with Compugen (Nasdaq:CGEN), as President, Compugen USA Inc. and Executive VP, Commercial Operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including J&J, Novartis, Teva, Abbott, Medarex and others. Erez earned his M.B.A., M.Sc. in Microbiology and his B.Sc. from Tel Aviv University.
Carl Goldfischer, MD
Carl Goldfischer is an Investment Partner and Managing Director of Bay City Capital, serving as a member of the board of directors and executive committee, and has been with the firm since December 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Dr. Goldfischer serves on the board of directors of numerous companies, including: BrainCells, EnteroMedics, Epizyme and Metabolex. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College.
Søren Møller, PhD
Søren Møller joined Novo A/S in 2011 as Managing Investment Director of Novo Seeds. Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine. Prior to joining Novo Seeds, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.